You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 160 No. 5, May 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (2)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Gastroenterology
 •Liver/ Biliary Tract/ Pancreatic Diseases
 •Genetics
 •Genetic Counseling/ Testing/ Therapy
 •Pediatrics, Other
 •Alert me on articles by topic

Genetic Testing of Minors for Alpha1-Antitrypsin Deficiency

Charlie Strange, MD; Mary Allison Moseley; Yonge Jones; Laura Schwarz; Lianqi Xie; Mark L. Brantly, MD

Arch Pediatr Adolesc Med. 2006;160:531-534.

Background  Alpha1-antitrypsin deficiency (AATD) is a genetic disorder primarily affecting the lungs and liver of affected individuals, causing severe panlobular emphysema and cirrhosis.

Objective  To describe the demographics and feasibility of a home test for AATD in children and adolescents.

Design  Case series of parents who test their children for AATD.

Setting  Nonprofit supported program in which participants telephoned or e-mailed requests for alpha1-antitrypsin testing.

Participants  All persons younger than 18 years whose parents or guardians chose to test for AATD from January 1, 2002, to October 1, 2004.

Interventions  Home-administered finger-stick blood spot test for alpha1-antitrypsin genotype and questionnaire.

Main Outcome Measures  The alpha1-antitrypsin genotypes and questionnaire responses.

Results  The Alpha Coded Testing Study tested 422 children and adolescents with a confidential test for AATD. Testing was suggested by a family member in most (76.7%) of the cases and was responsible for the many carrier (PIMZ and PIMS) genotypes (51.9%) in the study. Interest in testing was equally distributed among all ages. Test confidentiality was seen as an important reason to test (64.1% with a Likert scale score of 4-5 on a 5-point scale). Parents and guardians of the minors suggested that testing benefits (mean [SD] Likert score, 3.5 [1.4] on a 5-point scale) were higher than risks (mean [SD] Likert score, 1.7 [1.2]) (P=.001).

Conclusion  Parents value genetic testing of their children at risk for AATD when testing can be done in a confidential setting.


Author Affiliations: Division of Pulmonary and Critical Care Medicine (Dr Strange, Mss Moseley and Schwarz, and Mr Jones) and Department of Biometry (Ms Xie), Medical University of South Carolina, Charleston; and Division of Pulmonary and Critical Care Medicine, University of Florida Health Sciences Center at Gainesville (Dr Brantly).



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Screening and Familial Testing of Patients for {alpha}1-Antitrypsin Deficiency
Hogarth and Rachelefsky
Chest 2008;133:981-988.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.